vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Aterian, Inc. (ATER). Click either name above to swap in a different company.
Aterian, Inc. is the larger business by last-quarter revenue ($15.1M vs $10.7M, roughly 1.4× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs -52.5%, a 76.0% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs -38.5%). Over the past eight quarters, Arbutus Biopharma Corp's revenue compounded faster (-13.2% CAGR vs -13.5%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Aterian, Inc. is a technology-enabled consumer products company that leverages artificial intelligence and data analytics to identify market demand, develop, source and distribute a wide portfolio of affordable goods spanning home improvement, wellness, personal care, pet supplies and outdoor recreation. It primarily sells its products through leading global e-commerce platforms, with core markets covering North America and Europe.
ABUS vs ATER — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $15.1M |
| Net Profit | $2.5M | $-7.9M |
| Gross Margin | — | 56.1% |
| Operating Margin | 13.9% | -51.1% |
| Net Margin | 23.5% | -52.5% |
| Revenue YoY | 522.2% | -38.5% |
| Net Profit YoY | 112.7% | -512.2% |
| EPS (diluted) | $0.01 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $15.1M | ||
| Q3 25 | — | $19.0M | ||
| Q2 25 | $10.7M | $19.5M | ||
| Q1 25 | — | $15.4M | ||
| Q4 24 | — | $24.6M | ||
| Q3 24 | — | $26.2M | ||
| Q2 24 | — | $28.0M | ||
| Q1 24 | — | $20.2M |
| Q4 25 | — | $-7.9M | ||
| Q3 25 | — | $-2.3M | ||
| Q2 25 | $2.5M | $-4.9M | ||
| Q1 25 | — | $-3.9M | ||
| Q4 24 | — | $-1.3M | ||
| Q3 24 | — | $-1.8M | ||
| Q2 24 | — | $-3.6M | ||
| Q1 24 | — | $-5.2M |
| Q4 25 | — | 56.1% | ||
| Q3 25 | — | 56.1% | ||
| Q2 25 | — | 54.3% | ||
| Q1 25 | — | 61.4% | ||
| Q4 24 | — | 63.4% | ||
| Q3 24 | — | 60.3% | ||
| Q2 24 | — | 60.4% | ||
| Q1 24 | — | 65.1% |
| Q4 25 | — | -51.1% | ||
| Q3 25 | — | -10.7% | ||
| Q2 25 | 13.9% | -23.1% | ||
| Q1 25 | — | -24.1% | ||
| Q4 24 | — | -6.5% | ||
| Q3 24 | — | -6.6% | ||
| Q2 24 | — | -11.5% | ||
| Q1 24 | — | -26.1% |
| Q4 25 | — | -52.5% | ||
| Q3 25 | — | -12.0% | ||
| Q2 25 | 23.5% | -25.0% | ||
| Q1 25 | — | -25.4% | ||
| Q4 24 | — | -5.3% | ||
| Q3 24 | — | -6.8% | ||
| Q2 24 | — | -13.0% | ||
| Q1 24 | — | -25.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0.01 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $4.9M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $15.2M |
| Total Assets | $103.3M | $29.6M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $4.9M | ||
| Q3 25 | — | $7.6M | ||
| Q2 25 | $37.4M | $10.5M | ||
| Q1 25 | — | $14.3M | ||
| Q4 24 | — | $18.0M | ||
| Q3 24 | — | $16.1M | ||
| Q2 24 | — | $20.3M | ||
| Q1 24 | — | $17.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $15.2M | ||
| Q3 25 | — | $22.6M | ||
| Q2 25 | $83.0M | $24.3M | ||
| Q1 25 | — | $27.0M | ||
| Q4 24 | — | $30.0M | ||
| Q3 24 | — | $30.6M | ||
| Q2 24 | — | $30.9M | ||
| Q1 24 | — | $33.0M |
| Q4 25 | — | $29.6M | ||
| Q3 25 | — | $40.1M | ||
| Q2 25 | $103.3M | $45.4M | ||
| Q1 25 | — | $49.8M | ||
| Q4 24 | — | $49.5M | ||
| Q3 24 | — | $52.1M | ||
| Q2 24 | — | $59.9M | ||
| Q1 24 | — | $55.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $-1.0M |
| Free Cash FlowOCF − Capex | — | $-1.0M |
| FCF MarginFCF / Revenue | — | -6.9% |
| Capex IntensityCapex / Revenue | 0.0% | 0.0% |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-1.0M | ||
| Q3 25 | — | $-1.6M | ||
| Q2 25 | $-15.7M | $-4.4M | ||
| Q1 25 | — | $-3.9M | ||
| Q4 24 | — | $-9.0K | ||
| Q3 24 | — | $-722.0K | ||
| Q2 24 | — | $2.9M | ||
| Q1 24 | — | $-6.0K |
| Q4 25 | — | $-1.0M | ||
| Q3 25 | — | $-1.6M | ||
| Q2 25 | — | $-4.4M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $2.9M | ||
| Q1 24 | — | $-42.0K |
| Q4 25 | — | -6.9% | ||
| Q3 25 | — | -8.4% | ||
| Q2 25 | — | -22.7% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 10.3% | ||
| Q1 24 | — | -0.2% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABUS
Segment breakdown not available.
ATER
| Sales Channel Directly To Consumer | $13.1M | 87% |
| Heating Cooling And Air Quality | $2.1M | 14% |
